


FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
ELITRA.001AAPPLICATION NO.  
09/492,709SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Zyskind, et al.FILING DATE  
January 27, 2000GROUP  
1831

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

RECEIVED

APR 16 2003

TECH CENTER 1600/2000

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
AM	1 -	Bennett, F. C. 1998. Antisense oligonucleotides: Is the glass half full or half empty? <i>Biochemical Pharmacology</i> , 55:9-19.
AM	2 -	Crooke, S. T. 1998. An overview of progress in antisense therapeutics. <i>Antisense &amp; Nucleic Acid Drug Development</i> , 8:115-122.
AM	3 -	Gura, T. 1995. Antisense has growing pains. <i>Science</i> , 270:575-577.

S:\DOCS\DOH\DOH-7374.DOC:dmb  
032503

EXAMINER	<i>Adam Marschall</i>	DATE CONSIDERED	12-22-03
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			